关于心力衰竭中堵塞治疗的概述
Julia Martinez-Sole1, Jose Carlos Sanchez-Martinez1, Raquel Lopez-Vilella1
1Hospital Universitari i Politecnic La Fe, IIS La Fe, Valencia, Spain.
Current pharmaceutical design
|July 17, 2023
概括
管理心力衰竭拥堵至关重要. 本指南详细介绍了心力衰竭患者的利尿策略和新兴疗法,强调脏阻塞有效治疗.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭是发达国家普遍存在的疾病,导致大量住院治疗和医疗保健支出.
- 拥堵是心力衰竭最常见的症状,也是住院的主要驱动因素.
- 利尿剂,特别是循环利尿剂,对于控制心力衰竭相关的拥堵至关重要.
研究的目的:
- 介绍一个逐步的方法来管理心力衰竭患者的拥堵.
- 为指导医疗专业人员在心力衰竭管理的临床实践.
- 为了解决急性心力衰竭治疗缺乏明确算法的问题.
主要方法:
- 审查当前的利尿疗法,包括它们的机制,药理动力学和不良影响.
- 探索用于抗利尿剂病例的替代治疗方法,如超过和腹膜透析.
- 综合现有研究,提出一个实际的管理策略.
主要成果:
- 利尿剂仍然是急性心力衰竭的主要药理干预措施.
- 脏阻塞被认为是管理心力衰竭拥堵的关键组成部分.
- 新兴疗法为耐火病例提供了新的选择,尽管需要进一步的研究.
结论:
- 需要一种结构化的方法来管理心力衰竭拥堵,以优化患者的治疗结果.
- 虽然利尿剂是基础的,但对于复杂的病例,新的治疗策略是必不可少的.
- 持续的研究对于开发急性心力衰竭改善的管理方案至关重要.
相关概念视频
Heart Failure V: Medical Management
14
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
14
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure Drugs: β-Blockers
367
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
367
Heart Failure VII: Nursing Interventions
99
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
99
Heart Failure Drugs: Diuretics
424
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
424
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
465
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
465


